Respiratory Tract Neoplasms  >>  viagenpumatucel-L (HS-110)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
viagenpumatucel-L (HS-110) / NightHawk Biosci
NCT01504542: Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Withdrawn
2a
0
US
HS110 vaccine, Placebo
Heat Biologics
Non-small Cell Lung Cancer
12/13
12/13

Download Options